glp-1 drug news today 2025 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio GLP-1 Receptor Agonist Market Valued

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

Lilly showed in recently announced clinical trial results that patients who switched to orforglipron after losing weight on either Wegovy or Zepbound regained less weight than participants who switched to a placebo

Exp Drug Sci 2023

when you want longer sessions, you can adjust

Simon R, Lahiri SW

Gross Medicare Spending on Ozempic and Other GLP-1s Is Already Skyrocketing Even Though Medicare Cannot Cover The Drugs for Weight Loss A KFF analysis shows that gross total Medicare spending on Ozempic and other similar drugs has increased dramatically in recent years even though Medicare is explicitly prohibited by law from covering the drugs for obesity